Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Muggia

Showing results (291-300 of 317) with videos related to

Pageof 32
Sort By:
Cancer Research|April 1, 1989
Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humansJ Shani, J Bertram, C Russell, et al.
Journal of the National Cancer Institute|January 17, 1990
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinicianD D Von Hoff, J F Sandbach, G M Clark, et al.
The Journal of Urology|June 1, 1991
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup StudyD G McLeod, R B Weiss, D M Stablein, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity studyV K Israel, C Jiang, F M Muggia, et al.
Cancer Treatment Reports|January 1, 1979
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474)D F Chiuten, J M Bennett, R H Creech, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adductsI Gill, F M Muggia, P M Terheggen, et al.
Cancer Treatment Reports|July 1, 1978
Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26N M Gad-el-Mawla, F M Muggia, M R Hamza, et al.
Cancer Clinical Trials|January 1, 1981
Animal toxicology for early clinical trials with anticancer agentsM Rozencweig, D D Von Hoff, M J Staquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group studyF M Muggia, P S Braly, M F Brady, et al.
Pageof 32

Showing results (291-300 of 317) with videos related to

Sort By:
Pageof 32
Cancer Research|April 1, 1989
Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humansJ Shani, J Bertram, C Russell, et al.
Journal of the National Cancer Institute|January 17, 1990
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinicianD D Von Hoff, J F Sandbach, G M Clark, et al.
The Journal of Urology|June 1, 1991
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup StudyD G McLeod, R B Weiss, D M Stablein, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity studyV K Israel, C Jiang, F M Muggia, et al.
Cancer Treatment Reports|January 1, 1979
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474)D F Chiuten, J M Bennett, R H Creech, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adductsI Gill, F M Muggia, P M Terheggen, et al.
Cancer Treatment Reports|July 1, 1978
Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26N M Gad-el-Mawla, F M Muggia, M R Hamza, et al.
Cancer Clinical Trials|January 1, 1981
Animal toxicology for early clinical trials with anticancer agentsM Rozencweig, D D Von Hoff, M J Staquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group studyF M Muggia, P S Braly, M F Brady, et al.
Pageof 32